Immunogenicity and Safety Study of GSK Biologicals Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral (2013-2014 Season) in Adults Aged 18 Years and Older

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral (2013-2014 Season) in Adults Aged 18 Years and Older

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2015

At a glance

  • Drugs GSK 1536489A (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Jan 2015 Protocol has been amended in treatment table from 1 arm to 2 arms, addition of primary endpoints , change of trial focus from 'PD' to TU & PD' and change of intervention model from single group to parallel assignment.
    • 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top